| CDK12 Protein | |
|---|---|
| Protein Name | CDK12 (Cyclin-Dependent Kinase 12) |
| Gene | CDK12 |
| UniProt ID | Q9NYV4 |
| Molecular Weight | ~164 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | CDK family, CTD kinase family |
CDK12 (Cyclin-Dependent Kinase 12) is a serine/threonine kinase that plays a critical role in regulating gene transcription, particularly of DNA damage response genes. As a member of the cyclin-dependent kinase family, CDK12 phosphorylates the C-terminal domain (CTD) of RNA polymerase II, coordinating transcription elongation with RNA processing[1]. Emerging evidence links CDK12 dysfunction to neurodegenerative diseases, particularly through its regulation of genes involved in protein homeostasis and stress responses[2].
CDK12 contains an N-terminal regulatory domain, a central kinase domain, and a C-terminal extension that mediates protein-protein interactions. Unlike most CDKs, CDK12 associates with Cyclin K (CCNK) rather than cyclin E or cyclin A, forming an active complex that phosphorylates the heptad repeat YSPTSPS repeats of the RNA Pol II CTD[3].
The primary function of CDK12 is to phosphorylate Ser2 and Ser5 of the RNA Pol II CTD, marks associated with transcription elongation and co-transcriptional RNA processing. CDK12 specifically promotes the expression of long genes, particularly those involved in DNA repair, protein folding, and stress responses[4].
CDK12 activity appears dysregulated in Alzheimer's disease brain tissue. Studies have shown decreased CDK12 expression and altered phosphorylation of its target proteins in AD neurons[5]. This dysfunction may contribute to the impaired transcription of protective genes observed in AD, including those involved in protein quality control and synaptic function.
The connection between CDK12 and tau pathology is particularly intriguing. CDK12 can phosphorylate tau at several sites relevant to AD pathology, and its dysregulation may contribute to the accumulation of hyperphosphorylated tau in neurofibrillary tangles[6].
In Parkinson's disease, CDK12 may play protective roles through its regulation of genes involved in mitochondrial function and protein homeostasis. CDK12 inhibition in cellular models leads to increased sensitivity to mitochondrial toxins, while overexpression protects dopaminergic neurons from oxidative stress[7].
CDK12 has been implicated in ALS through its regulation of genes involved in RNA metabolism and protein aggregation. Mutations in genes encoding RNA-binding proteins are a known cause of familial ALS, and CDK12 dysfunction may exacerbate RNA processing defects in this disease[8].
CDK12 represents a challenging but potentially valuable therapeutic target. Global CDK12 inhibition would be toxic due to its essential role in transcription, but targeted approaches that enhance specific protective functions might be beneficial. Understanding the cell-type-specific roles of CDK12 in neurons versus glia will be crucial for developing targeted therapies[9].
Blazek et al. The Cyclin K/CDK12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes & Development. 2011. ↩︎ ↩︎
Koh et al. CDK12: a key transcriptional regulator in neurodegenerative diseases. Frontiers in Molecular Neuroscience. 2022. ↩︎ ↩︎
Cheng et al. Cyclin K-containing cyclin-dependent kinase complexes function in transcription regulation. Journal of Biological Chemistry. 2012. ↩︎ ↩︎
Bartkowiak et al. CDK12 is a transcription elongation-associated CTD kinase. Cell. 2010. ↩︎ ↩︎
Zhang et al. Dysregulation of CDK12 in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2021. ↩︎ ↩︎
Liu et al. CDK12-mediated tau phosphorylation in Alzheimer's disease. Neurobiology of Disease. 2020. ↩︎
Chen et al. CDK12 protects dopaminergic neurons from oxidative stress via regulation of mitochondrial genes. Cell Death & Disease. 2022. ↩︎
Wang et al. CDK12 and RNA metabolism in amyotrophic lateral sclerosis. Brain Research. 2021. ↩︎
Johnson et al. Targeting transcriptional kinases in neurodegenerative diseases. Nature Reviews Drug Discovery. 2023. ↩︎